rial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024
Future development of IV ganaxolone in refractory status epilepticus to be assessed following review of the final RAISE results
Enrollment in the TrustTSC trial expected to complete mid-May with topline data on track for the first half of Q4 2024
Cost reduction activities to extend cash runway are under review and expected to be implemented Q2 2024
ZTALMY® (ganaxolone) Q1 2024 preliminary net product revenue of between $7.4 and $7.6 million; preliminary unaudited cash, cash equivalents and short-term investments of $113.3 million as of March 31, 2024
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.